RICHLAND, WASHINGTON – January 7, 2021 – Isoray, Inc. (NYSE American: ISR), a medical technology company and seed brachytherapy innovator powering expanding treatment options throughout the body, today announced that Chief Executive Officer Lori Woods will present at...
Studies Demonstrate Impact of Proprietary Isotope on Prostate and Brain Cancers At World’s Premier Radiation Oncology Society RICHLAND, WASHINGTON – November 24, 2020 – The importance of Isoray, Inc.’s (NYSE American: ISR) Cesium-131 in treating prostate and brain...
Revenue Increased 3% Year-Over-Year Non-Prostate Brachytherapy Revenue Increased 104% Year-Over-Year RICHLAND, WASHINGTON – November 10, 2020 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding...
Conference Call is Tuesday, November 10, 2020 at 4:30 p.m. ET/1:30 p.m. P RICHLAND, WASHINGTON – November 2, 2020 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a conference call...
RICHLAND, Wash., October 20, 2020 - Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, announced the pricing of its public offering of 18,269,230 shares of its...
RICHLAND, Wash., October 19, 2020 -- Isoray, Inc. (NYSE AMERICAN: ISR) (“Isoray” or the “Company”), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that it intends to offer and...
Record Full Year Revenue and Gross Profit Full Year Revenue Increased 32% Year-Over-Year RICHLAND, WASHINGTON – September 17, 2020 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment...
RICHLAND, WASHINGTON – September 16, 2020 – Isoray, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that Chief Executive Officer Lori...
Conference Call is Thursday, September 17, 2020, at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – September 10, 2020 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a...
Trial Will Evaluate Use of Pembrolizumab, Known as Keytruda®*, With Cesium-131 and Surgical Resection RICHLAND, Wash., June 17, 2020 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE American: ISR) today announced that it has entered into a research grant agreement with the...
RICHLAND, WASHINGTON – June 2, 2020 – Isoray, Inc. (NYSE American: ISR) today announced that the results of a new ten year study show positive outcomes for low-risk and intermediate-risk prostate cancer patients treated with Isoray’s Cesium-131 (Cesium Blu) internal...
RICHLAND, WASHINGTON – May 12, 2020 – Isoray, Inc. (NYSE American: ISR) today announced that the Centers for Medicare and Medicaid Services (CMS) has approved 64 ICD-10-PCS billing codes used for reimbursement of Cesium-131 (Cesium Blu™) for the hospital in-patient...
Record Revenue and Gross Profit Revenue Increased 50% Year-Over-Year RICHLAND, WASHINGTON – May 12, 2020 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body,...